Literature DB >> 7810805

High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1.

A W Thomas1, J F Trape, C Rogier, A Goncalves, V E Rosario, D L Narum.   

Abstract

The 83-kilodalton (kD) apical membrane antigen of Plasmodium falciparum (PF83/AMA-1) is a potential asexual blood stage vaccine component. This antigen has been expressed as a full-length, nonfusion, recombinant baculovirus protein (PF83-7G8-1) using the authentic predicted signal peptide for appropriate postsynthetic routing. When purified by a novel high-performance, ion exchange chromatography (HPIEC) method, PF83-7G8-1 induced polyclonal antibodies in rats that immunoprecipitated both 83- and 66-kD forms of PF83/AMA-1 from 35S-methionine metabolically labeled parasite extracts. Using HPIEC-purified PF83-7G8-1 in combination with a rat monoclonal antibody against the highly conserved carboxy-terminal (CT) region of PF83/AMA-1, we developed a CT-capture-enzyme-linked immunosorbent assay to measure naturally acquired responses against the entire PF83/AMA-1 molecule. Analysis of populations from villages in Guinea-Bissau and in an area of high malarial transmission in Senegal demonstrated a very high prevalence (94-100%) of naturally acquired serum IgG responses to PF83/AMA-1. Analysis of these natural responses showed that PF83/AMA-1 may be a well-recognized asexual parasite antigen. A statistically significant age-related change in antibody levels to PF83/AMA-1 was observed in Guinea-Bissau. No such correlation was observed in the Senegalese population, although an age-related antibody response was seen for total parasite antigen. No significant correlation was observed between PF83/AMA-1 responses and the parameters of parasite load and malaria-related fever.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810805     DOI: 10.4269/ajtmh.1994.51.730

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  45 in total

1.  Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene.

Authors:  S D Polley; D J Conway
Journal:  Genetics       Date:  2001-08       Impact factor: 4.562

2.  Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1.

Authors:  Alfred Cortés; Mata Mellombo; Ivo Mueller; Ariadna Benet; John C Reeder; Robin F Anders
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

3.  Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.

Authors:  Alfred Cortés; Mata Mellombo; Rosella Masciantonio; Vince J Murphy; John C Reeder; Robin F Anders
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Binding hot spot for invasion inhibitory molecules on Plasmodium falciparum apical membrane antigen 1.

Authors:  Karen S Harris; Joanne L Casey; Andrew M Coley; Rosella Masciantonio; Jennifer K Sabo; David W Keizer; Erinna F Lee; Andrew McMahon; Raymond S Norton; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka.

Authors:  Thilan Wickramarachchi; Prasad H Premaratne; K L R Lakshman Perera; Sumith Bandara; Clemens H M Kocken; Alan W Thomas; Shiroma M Handunnetti; Preethi V Udagama-Randeniya
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.

Authors:  Abdoreza Davoodi-Semiromi; Melissa Schreiber; Samson Nalapalli; Dheeraj Verma; Nameirakpam D Singh; Robert K Banks; Debopam Chakrabarti; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2009-12-28       Impact factor: 9.803

7.  High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.

Authors:  Sheetij Dutta; JoAnn S Sullivan; Katharine K Grady; J David Haynes; Jack Komisar; Adrian H Batchelor; Lorraine Soisson; Carter L Diggs; D Gray Heppner; David E Lanar; William E Collins; John W Barnwell
Journal:  PLoS One       Date:  2009-12-03       Impact factor: 3.240

8.  Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Mady Sissoko; Dapa A Diallo; Issa Diarra; Bourema Kouriba; Modibo Daou; Amagana Dolo; Mounirou Baby; Mahamadou S Sissoko; Issaka Sagara; Amadou Niangaly; Idrissa Traore; Ally Olotu; Olivier Godeaux; Amanda Leach; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Shannon L Takala; Kirsten E Lyke; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

9.  Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.

Authors:  Amed Ouattara; Jianbing Mu; Shannon Takala-Harrison; Renion Saye; Issaka Sagara; Alassane Dicko; Amadou Niangaly; Junhui Duan; Ruth D Ellis; Louis H Miller; Xin-zhuan Su; Christopher V Plowe; Ogobara K Doumbo
Journal:  Malar J       Date:  2010-06-21       Impact factor: 2.979

10.  Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.

Authors:  Martha Sedegah; Yohan Kim; Bjoern Peters; Shannon McGrath; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna Banania; Maria Belmonte; Renato Sayo; Fouzia Farooq; Denise L Doolan; David Regis; Cindy Tamminga; Ilin Chuang; Joseph T Bruder; C Richter King; Christian F Ockenhouse; Bart Faber; Edmond Remarque; Michael R Hollingdale; Thomas L Richie; Alessandro Sette
Journal:  Malar J       Date:  2010-08-24       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.